Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 3/20 | 0.35 |
| ▸ | TCF4 | P15884 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180266 | 1.00 | KDR (0.39) | KDRCHEK2AURKATCF4CTNNB1 | |
| SCHEMBL23999929 | 0.89 | HPSE (0.41) | KDRCHEK2NPC1PKMRAB9A | |
| SCHEMBL30180637 | 0.87 | KDR (0.45) | KDRAURKATCF4CTNNB1NPC1 | |
| SCHEMBL23999674 | 0.87 | KDR (0.45) | KDRAURKATCF4CTNNB1NPC1 | |
| SCHEMBL30180512 | 0.84 | KDR (0.39) | KDR | |
| SCHEMBL23999654 | 0.84 | KDR (0.39) | KDR | |
| SCHEMBL30180554 | 0.83 | KDR (0.36) | KDR | |
| SCHEMBL23999928 | 0.83 | KDR (0.36) | KDR | |
| SCHEMBL24004081 | 0.83 | KDR (0.35) | KDR | |
| SCHEMBL23999658 | 0.81 | KDR (0.41) | KDRAURKATCF4CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226517-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3433/4885CHEK2 356/4885AURKA 2590/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3271/4885CHEK2 332/4885AURKA 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.